Custom Chemicals for Biotech Startups

The Biotech Startup Procurement Challenge

Biotech startups face a procurement paradox. The compounds they need are often more complex than what large pharmaceutical companies order at the same stage, because startups typically pursue novel modalities and underexplored targets to differentiate themselves. Yet startups have fewer resources to manage the procurement process: no dedicated sourcing team, limited vendor relationships, and budgets measured in thousands rather than millions of dollars.

The result is that many early-stage biotechs either overpay for custom synthesis, accept suboptimal quality because they did not specify requirements precisely enough, or waste months working with partners whose capabilities do not match the project’s demands. Each of these outcomes burns cash and delays programs in an environment where every month matters.

Understanding the custom synthesis process — what to ask for, what to expect, and what to watch out for — gives biotech teams a significant operational advantage.

Typical Small-Batch Requirements for Early-Stage Biotechs

Quantity Ranges

Most biotech startups need custom compounds in quantities ranging from 1 gram to 100 grams. The specific quantity depends on the intended use:

• 1-5 grams: Sufficient for initial in vitro screening, binding assays, and preliminary ADMET profiling. This is the most common starting point for hit validation and early SAR studies.
• 5-25 grams: Supports expanded biological testing, selectivity panels, preliminary formulation studies, and early pharmacokinetic experiments in rodent models.
• 25-100 grams: Required for dose-ranging studies in animal models, GLP toxicology study material preparation, and the generation of stability data for regulatory planning.

Some biotechs need even smaller quantities — 100 milligrams to 1 gram — for analytical reference standards or proof-of-concept work. Reputable synthesis partners should accommodate these requests without imposing arbitrary minimum order quantities that force startups to purchase more than they need.

Purity Expectations

Purity requirements for biotech applications are typically stringent, even at early stages. The reason is straightforward: biological assay data generated with impure compound is unreliable and may lead to incorrect conclusions about a molecule’s activity or toxicity profile. Confirming purity through rigorous analytical testing is essential at every stage.

Standard purity targets by application:

Application	Typical Purity Target	Key Analytical Methods
In vitro screening	≥95% by HPLC	HPLC, LC-MS, 1H NMR
Cell-based assays	≥95% by HPLC	HPLC, LC-MS, 1H NMR
In vivo PK studies	≥97% by HPLC	HPLC, LC-MS, NMR (1H, 13C)
GLP toxicology studies	≥98% by HPLC	HPLC, LC-MS, NMR, elemental analysis
IND-enabling studies	≥98% by HPLC, characterized impurities	Validated HPLC, LC-MS/MS, NMR, KF, residual solvents

A common mistake startups make is under-specifying purity. Requesting “high purity” without a numerical target and defined analytical method leaves the synthesis partner guessing and often leads to disputes when material is delivered. Always specify purity as a number, the analytical method used to measure it, and any specific impurities that must be controlled (e.g., “≥97% by HPLC at 254 nm, with no single impurity >0.5%”).

Compound Classes Commonly Needed by Biotechs

The types of custom compounds biotech startups require reflect the modalities and target classes that dominate current drug discovery. Understanding your compound class helps you select a synthesis partner with relevant expertise.

Heterocyclic Scaffolds

Heterocyclic compounds remain the backbone of small-molecule drug discovery. Startups working on kinase inhibitors, GPCR modulators, and epigenetic targets routinely need custom analogs built around pyrimidine, pyrazole, indazole, quinazoline, benzimidazole, and imidazo[1,2-a]pyridine cores. These scaffolds require expertise in palladium-catalyzed cross-coupling reactions (Suzuki-Miyaura, Buchwald-Hartwig amination), directed C-H functionalization, and regioselective functionalization of polyheteroaromatic systems.

A synthesis partner experienced in heterocyclic chemistry should be able to propose efficient routes that minimize step count while maximizing flexibility for analog generation — enabling a startup to explore SAR around a hit without commissioning a separate synthesis for every analog.

PROTAC Components and Molecular Glues

Targeted protein degradation has emerged as one of the most active areas of biotech investment. PROTACs (Proteolysis-Targeting Chimeras) are bifunctional molecules composed of three elements: a target-binding ligand (warhead), an E3 ligase-binding ligand (typically a VHL or cereblon binder), and a chemical linker connecting the two. Each component may need to be synthesized individually, and the final PROTAC must be assembled with precise control over linker length, composition, and attachment chemistry.

Common PROTAC-related synthesis requests include:

• VHL ligands (e.g., VH032 and analogs): Require stereocontrolled synthesis of hydroxyproline-containing peptidomimetics
• Cereblon binders (thalidomide, pomalidomide, lenalidomide analogs): Involve glutarimide chemistry with specific stereochemical requirements
• PEG-based linkers of defined length (PEG2 through PEG12): Need high-purity discrete PEG chains, not polydisperse mixtures
• Alkyl and heteroatom-containing linkers: Require click chemistry handles (azides, alkynes) or reactive functional groups for bioconjugation

PROTAC synthesis is technically demanding because the final molecules are large (typically 700-1,200 Da), often poorly soluble, and require multistep sequences with late-stage coupling reactions that must proceed cleanly to avoid difficult purifications. Startups should verify that a synthesis partner has specific PROTAC experience, not just general organic synthesis capability. For large analog series, combinatorial chemistry approaches can accelerate PROTAC linker exploration significantly.

Peptide Building Blocks and Unnatural Amino Acids

Startups developing peptide therapeutics, peptide-drug conjugates, or macrocyclic peptides frequently need custom amino acid derivatives that are not commercially available. Common requests include N-methylated amino acids, D-amino acids with non-standard side chains, alpha-methylated amino acids for conformational constraint, and Fmoc- or Boc-protected unnatural amino acids with orthogonal side-chain protection.

These compounds require stereoselective synthesis (often asymmetric hydrogenation, enzymatic resolution, or chiral auxiliary-based methods) and rigorous enantiomeric purity verification by chiral HPLC or SFC. A single percentage point of enantiomeric impurity in a building block can propagate through peptide assembly and compromise the biological activity of the final product.

Linker-Payload Compounds for ADCs

Antibody-drug conjugates (ADCs) are a growing focus for biotech startups, particularly following the commercial success of Enhertu (trastuzumab deruxtecan) and Padcev (enfortumab vedotin). Custom synthesis needs in this area include cytotoxic payloads (MMAE, MMAF, DXd, exatecan analogs, PBD dimers), cleavable and non-cleavable linker constructs (maleimide-caproyl-valine-citrulline-PABC and variants), and linker-payload conjugates ready for antibody attachment.

ADC linker-payload synthesis requires handling highly cytotoxic compounds under appropriate containment conditions (typically OEB4 or OEB5 engineering controls). Not all synthesis partners are equipped for potent compound handling — this is a critical capability to verify before engaging a partner for ADC chemistry.

How to Spec a Custom Synthesis Project

The quality of your project specification directly determines the quality of the quotes you receive, the accuracy of timelines, and the likelihood of a successful outcome. A well-written synthesis request should include the following elements.

Molecular Structure and Characterization

Provide the target structure in a machine-readable format (SMILES, InChI, or MOL file) in addition to a drawn structure. If stereochemistry is defined, specify it explicitly — do not assume the synthesis partner will know which enantiomer you need. If you need a racemate, state that clearly to avoid unnecessary chiral resolution costs.

Include any available literature references for the compound or closely related analogs. If the compound has been previously synthesized, cite the publication and synthetic route. If this is a novel structure, provide any retrosynthetic analysis or route suggestions your team has considered. This information helps the synthesis partner evaluate feasibility quickly and reduces the time spent on route scouting.

Purity and Analytical Requirements

Define your purity specification quantitatively and specify the analytical deliverables you require:

• Minimum acceptable purity: e.g., ≥97% by HPLC (specify UV wavelength or detection method)
• Chiral purity: e.g., ≥99% ee by chiral HPLC or SFC (if applicable)
• Identity confirmation: 1H NMR, 13C NMR, HRMS (specify which are required vs. nice-to-have)
• Specific impurity limits: If certain structural impurities are known to interfere with your assays, specify limits for those specific compounds
• Certificate of Analysis format: Specify if you need a particular CoA format for regulatory or quality system purposes

Quantity and Packaging

Specify the quantity needed, including whether you need the material in a single lot or divided into aliquots. If you plan to perform long-term stability studies, request material packaged under inert atmosphere (nitrogen or argon) in amber vials. Specify any storage and shipping temperature requirements.

Timeline and Milestones

Provide your target delivery date and indicate whether it is firm (tied to a specific animal study start date, for example) or flexible. If you have intermediate milestones — such as a need for an initial 100 mg sample for assay development before the full quantity is delivered — communicate those upfront. Staggered delivery can sometimes reduce overall timeline risk.

Budget Constraints

Being transparent about your budget is not a weakness — it is practical. If your total budget for a compound is $8,000, saying so upfront prevents the partner from proposing a 12-step synthesis that would cost $25,000. A good synthesis partner can often suggest alternative approaches (shorter routes, lower-cost starting materials, reduced analytical packages) that fit within a startup’s budget while still delivering usable material.

Budget Realities for Startup Compounds

Custom synthesis costs are driven primarily by molecular complexity, step count, and the availability of starting materials. Understanding the cost landscape helps startups budget realistically and avoid sticker shock.

Typical Cost Ranges

Compound Complexity	Step Count	Typical Cost (1-10 g)	Typical Timeline
Simple building blocks (substituted aromatics, protected amino acids)	1-3 steps	$1,500-$5,000	1-3 weeks
Moderate complexity (heterocyclic analogs, functionalized scaffolds)	4-6 steps	$5,000-$15,000	3-6 weeks
High complexity (PROTACs, macrocycles, stereoselective synthesis)	7-12 steps	$15,000-$40,000	6-12 weeks
Very high complexity (natural product analogs, ADC payloads)	10-20+ steps	$30,000-$80,000+	8-16 weeks

These ranges assume gram-scale delivery. Milligram-scale work is often 30-50% less expensive due to lower material costs and faster execution, while 100-gram quantities may be 2-3x the cost of gram-scale due to process optimization requirements.

How to Reduce Costs Without Compromising Quality

Several strategies can help budget-constrained startups get more value from their synthesis spending:

• Order analogs in series, not individually: If you need 5 analogs around a common scaffold, ordering them as a set from a single partner is 20-40% cheaper than ordering each separately, because the partner amortizes route development and starting material procurement across all compounds.
• Accept racemic material when possible: If you are in early screening and enantiomeric resolution is not yet required, specify a racemate. Chiral resolution or asymmetric synthesis can add 30-50% to project costs.
• Tier your analytical requirements: Full NMR characterization (1H, 13C, DEPT, COSY, HSQC, HMBC) costs significantly more than 1H NMR plus HRMS. Use the full package for your lead compound and a reduced package for screening analogs.
• Provide starting materials if available: If your lab already has an intermediate or a key building block on hand, shipping it to your synthesis partner eliminates procurement cost and lead time.
• Plan ahead: Rush fees (for delivery faster than the partner’s standard timeline) typically add 25-50% to project costs. Building synthesis into your project plan with adequate lead time avoids these premiums.

IP Protection When Working Without a Full Legal Team

Intellectual property protection is among the top concerns for biotech startups engaging external synthesis partners, and rightly so. Your novel compounds may represent the core value of your company, and premature disclosure or inadequate IP protection could jeopardize your patent position or competitive advantage.

Confidential Disclosure Agreements

Before sharing any structural information with a synthesis partner, execute a mutual confidential disclosure agreement (CDA) or non-disclosure agreement (NDA). The agreement should cover:

• Definition of confidential information: Broadly defined to include compound structures, synthetic routes, biological data, and business information
• Permitted use: Limited to evaluating and executing the synthesis project
• Term: Typically 3-5 years for the confidentiality obligation, though trade secret protection should extend indefinitely
• Return or destruction of information: Upon project completion or termination, the partner should return or certify destruction of all confidential materials and information
• Exclusions: Standard carve-outs for information that becomes publicly available, was independently developed, or was already known to the recipient

Most reputable synthesis partners have standard CDAs available. Review them carefully — some partner-drafted agreements include broad exclusions or short confidentiality terms that may not adequately protect startup IP.

Invention Assignment

Your contract with the synthesis partner should include clear invention assignment provisions stating that all inventions, improvements, and know-how generated during the project are assigned to you (the client). This includes novel synthetic intermediates, process improvements, and any unexpected compounds discovered during the synthesis. Without explicit assignment language, inventions made by the partner’s chemists during your project may belong to the partner under default employment and IP law.

Patent Filing Timing

If your compound structures are patentable, consider filing provisional patent applications before disclosing structures to external partners. A provisional application establishes a priority date and provides 12 months to file a full application, giving you freedom to engage synthesis partners without risking your patent position. The cost of a provisional filing ($2,000-$5,000 for attorney fees plus USPTO fees) is insignificant compared to the value of securing your IP priority date.

Physical and Data Security

Ask your synthesis partner about their physical security measures (badge access, project segregation, visitor policies) and data security practices (encrypted file transfer, access-controlled ELN systems, data backup and retention policies). For particularly sensitive compounds, request that the partner assign dedicated staff to your project and restrict access to your structural information within their organization.

Working Without a Procurement Team

Most biotech startups under 30 employees do not have a dedicated procurement function. Compound sourcing is typically handled by a bench scientist, a project leader, or occasionally the CSO directly. This is not necessarily a disadvantage — in fact, having technically fluent people manage vendor relationships often leads to better project outcomes than routing requests through a non-technical procurement intermediary.

Streamlining the Vendor Evaluation Process

Evaluating synthesis partners does not require a formal RFP process or months of vendor qualification. For early-stage work, a practical evaluation can be completed in 1-2 weeks:

1. Identify 2-3 candidate partners through peer recommendations, scientific publications, or industry directories. Domestic (U.S.-based) partners simplify logistics, communication, and IP protection.
2. Send the same project specification to each partner and compare proposals on price, timeline, proposed route, analytical deliverables, and communication responsiveness.
3. Ask for relevant case studies: Has the partner synthesized compounds in your structural class before? Can they provide (anonymized) examples of similar projects?
4. Check references: Ask each partner for 2-3 client references, preferably from other biotech startups. The partner’s responsiveness and communication style with small clients may differ significantly from how they handle large pharma accounts.
5. Start with a small project: Before committing to a major synthesis campaign, test the relationship with a single compound order. Evaluate not just the product quality but the communication experience — were updates proactive? Were problems flagged early? Was the timeline met?

Managing the Relationship

Effective vendor management for a startup does not require complex systems. A few practices make a significant difference:

• Designate a single point of contact: One person on your team should own the relationship with each synthesis partner. This prevents duplicate communications and ensures continuity.
• Request weekly written updates: Even if there is nothing new to report, a brief weekly email from the partner confirms that the project is on track and maintains engagement.
• Document everything: Keep a simple log of what was ordered, what was delivered, costs, timelines, and any issues encountered. This becomes invaluable as your compound library grows and you need to reorder or scale up.
• Build the relationship: The synthesis partners who deliver the best results for startups are the ones who understand your program context. Share enough scientific background for the partner’s chemists to make intelligent decisions when unexpected problems arise during synthesis.

Minimum Order Expectations: What to Watch For

Some synthesis providers impose minimum order values that can be problematic for startups. Common minimum order structures include:

• Per-compound minimums: Some CROs will not accept projects below $5,000-$10,000 per compound. This may be reasonable for complex molecules but is excessive for straightforward 2-3 step syntheses.
• Program minimums: Some partners require a minimum annual commitment of $50,000-$100,000 before accepting any work. This effectively excludes early-stage startups.
• FTE-based minimums: Some CROs only operate on an FTE model with minimum 0.5 or 1.0 FTE commitments ($100,000-$300,000 per year). This model is inappropriate for startups with sporadic, project-based synthesis needs.

The best synthesis partners for startups offer project-based pricing with no arbitrary minimums, allowing you to start with a single compound and scale the relationship as your needs grow.

Selecting the Right Analytical Package

Analytical characterization is not a one-size-fits-all proposition. The appropriate analytical package depends on how the compound will be used, and over-specifying analytics wastes money while under-specifying creates risk.

Tiered Analytical Packages

Tier	Deliverables	Appropriate Use	Typical Add-On Cost
Basic	1H NMR, LC-MS, HPLC purity	Initial screening compounds, building blocks	Included in synthesis cost
Standard	1H and 13C NMR, HRMS, HPLC with purity ≥95%	Lead compounds, SAR studies, in vivo PK	$500-$1,500 per compound
Comprehensive	Full NMR suite, HRMS, chiral HPLC/SFC, residual solvents (GC-HS), KF water content, DSC/TGA	GLP studies, IND-enabling material	$2,000-$5,000 per compound
Regulatory	All comprehensive plus validated methods, stability-indicating HPLC, ICH Q3A/Q3B impurity profiling	Clinical trial material, regulatory submissions	$5,000-$15,000+ per compound

For most startup applications, the Standard tier provides the right balance of characterization and cost. Reserve the Comprehensive and Regulatory tiers for your lead compound as it advances toward IND-enabling studies.

Common Pitfalls and How to Avoid Them

Pitfall 1: Choosing a Partner Based on Price Alone

The cheapest quote often comes from a partner who has underestimated the project’s complexity, plans to cut corners on analytical characterization, or operates in a jurisdiction with weaker IP protection. A synthesis failure at the lowest bidder costs more than a successful synthesis at a moderately priced partner, because you lose both money and time.

Pitfall 2: Insufficient Structural Characterization

Accepting a compound with only LC-MS confirmation is risky. Mass spectrometry confirms molecular formula but not structure — it cannot distinguish between regioisomers, geometric isomers, or other structural variants that share the same molecular weight. At minimum, require 1H NMR to confirm the gross structure of any compound destined for biological testing.

Pitfall 3: Ignoring Salt Form and Counterion

If your compound contains a basic amine or acidic functionality, the material may be delivered as a salt (hydrochloride, trifluoroacetate, sodium, etc.) unless you specify the free base or free acid form. The counterion can significantly affect solubility, stability, and potency measurements. TFA salts are particularly problematic because residual TFA can interfere with cell-based assays. Specify the desired form in your project request.

Pitfall 4: No Contingency for Synthesis Failure

Not every synthesis succeeds on the first attempt. Complex molecules may require route modifications, alternative reagents, or additional optimization. Build contingency time (2-4 weeks) and budget (15-25% of the quoted price) into your project plan. Discuss upfront with your synthesis partner how they handle mid-project route changes: Is there a change order process? Are additional costs communicated before being incurred?

Pitfall 5: Neglecting Long-Term Supply Planning

If a compound shows promising biological activity, you will need more of it — potentially much more, and on a compressed timeline. Discuss scale-up feasibility with your synthesis partner at the outset. A route that works at 5 grams but cannot be scaled to 500 grams without a complete redesign creates a bottleneck exactly when your program is gaining momentum. Understanding process chemistry optimization from the beginning saves startups from costly route changes down the road.

Building a Long-Term Synthesis Partner Relationship

The most successful biotech-synthesis partner relationships are not transactional — they are collaborative. A synthesis partner who understands your therapeutic area, your target biology, and your development timeline can add value beyond simply executing reactions.

Signs of a partner worth investing in long-term:

• They ask questions about your project context, not just the structure to be synthesized
• They proactively suggest route alternatives that improve cost, timeline, or scalability
• They flag potential issues (solubility, stability, regiochemistry ambiguity) before they become problems
• They maintain detailed records that support your regulatory filings as compounds advance
• They can scale with you from milligram discovery work through kilogram GMP production
• They communicate consistently, whether the news is good or bad

Frequently Asked Questions

How much does custom chemical synthesis cost for a biotech startup?

Custom synthesis costs depend on molecular complexity, step count, and quantity. Simple 1-3 step building blocks at gram scale typically cost $1,500-$5,000, while complex molecules like PROTACs or ADC payloads requiring 7-12 steps may cost $15,000-$40,000. Ordering analog series from a single partner can reduce per-compound costs by 20-40%.

What is the typical turnaround time for small-batch custom synthesis?

Turnaround times range from 1-3 weeks for simple building blocks to 8-16 weeks for very high-complexity compounds like natural product analogs. Most biotech startup projects involving moderate-complexity heterocyclic analogs are completed in 3-6 weeks. Rush timelines are possible but typically add 25-50% to the project cost.

How do I protect my IP when outsourcing synthesis to an external partner?

Execute a mutual confidential disclosure agreement before sharing any structural information. Ensure your contract includes explicit invention assignment provisions covering all novel compounds, intermediates, and process improvements. Consider filing provisional patent applications before disclosing structures to establish a priority date.

What purity level should I specify for screening compounds?

For initial in vitro screening, specify a minimum of 95% purity by HPLC with identity confirmation by 1H NMR and LC-MS. Always provide a numerical target, the analytical method, and any specific impurity limits rather than requesting vague “high purity.” Under-specifying leads to disputes and unreliable assay data.

Do I need a procurement team to source custom compounds?

No. Most biotech startups under 30 employees handle compound sourcing through a bench scientist or project leader. Having technically fluent people manage vendor relationships often leads to better outcomes than routing requests through non-technical procurement intermediaries. Start with a single test project to evaluate a partner before committing to larger campaigns.

Why ChemContract for Biotech Startups

ChemContract is built to serve the needs of early-stage life sciences companies alongside our established pharmaceutical and chemical industry clients. Our approach for biotech startups emphasizes accessibility, transparency, and scientific partnership.

• No minimum order requirements: We accept single-compound projects starting from milligram quantities, with project-based pricing that respects startup budgets
• Deep expertise in current biotech modalities: Our chemists have demonstrated experience synthesizing PROTACs, ADC linker-payloads, unnatural amino acids, heterocyclic kinase inhibitor scaffolds, and other compound classes that biotech startups need most
• Comprehensive in-house analytical capabilities: HPLC, LC-MS, NMR (1H, 13C, 2D experiments), HRMS, chiral HPLC, SFC, GC-MS, KF titration, and DSC/TGA — all under one roof for rapid turnaround
• Robust IP protection: Mutual CDAs executed before any structural information is shared, with full invention assignment, secure data handling, and project-segregated laboratory operations
• Scalability: As your compound advances, we provide a seamless pathway from gram-scale discovery through kilogram-scale GMP production — eliminating the technology transfer delays and information loss that occur when switching vendors at scale transitions
• U.S.-based operations: Domestic synthesis eliminates tariff exposure, customs delays, shipping risks for temperature-sensitive materials, and the time zone challenges that complicate communication with offshore providers

For biotech startups navigating the custom synthesis landscape for the first time, ChemContract provides the combination of scientific expertise, operational flexibility, and commercial accessibility that early-stage companies need to move their programs forward efficiently. Browse our catalog of 7,000+ compounds or contact us to discuss your project.